RankAlpha logo
Back to Rankings

PEPG

PepGenF
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
View Chart
+
Peers tracked
10
U.S. public peers
Grade Position
Below peers
vs peer average
PEPG vs peer average
32/100
PEPG vs. peer average (F vs. D)
Grade spread
A 1 · B 1 · D 4 · F 4
Graded peers loaded
Coverage
10 graded
100% of tracked

Peer overview

RNA is the first available peer comparator.

Avidity is a direct DM1 operating comparator because PepGen identifies del-desiran/AOC 1001 as a Phase 3 clinical program competing against PepGen's DM1 candidate, making RNA the clearest category benchmark for speed and perceived efficacy leadership [#10-K-2026-03-04].

✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
Top peerRNAAtrium Therapeutics
PEPG
PepGen
RNA
Atrium Therapeutics
Grade
F
D
Momentum
33
18
Value
41
59
Sentiment
20
49
Setup Bias
Net —
-
Market Cap
-
-
Posture
Defensive
Defensive
Open Side-by-Side ComparisonCompare all

Grade position vs RNA

PEPG / RNA
Grade Position
Below peers
PEPG vs. peer average (F vs. D)
32/100
Momentum
33
PEPG
Value
41
RNA
Sentiment
20
RNA

Rotation landscape

Peers ranked by the order returned from the peer source, with grades from the API.

Rank
Ticker
Company
Grade
Grade score
vs PEPG
1
RNA
RNA
D
40/100
-1
2
TRDA
TRDA
F
20/100
Even
3
RCEL
AVITA Medical Inc Common
D
40/100
-1
4
IMDX
Insight Molecular Diagnostics Inc Common
F
20/100
Even
5
KZIA
Kazia Therapeutics Ltd ADR
D
40/100
-1
RNA is the first peer returned for this comparison set.